Biotech, National Security, and Global Competition | Dr. Rozo (NSCEB) | JPM Re-Air

In this special re-air of the Making Medicine Podcast, we revisit a timely conversation with Dr. Michelle Rozo of the National Security Commission on Emerging Biotechnology NSCEB, originally recorded live at JPM 2026.We are re-airing this episode in recognition of a recent roundtable hosted on Capitol Hill by the Incubate Coalition and NSCEB, where these same themes took center stage. As policymakers, investors, and industry leaders increasingly focus on the intersection of biotechnology and national security, this discussion offers critical context on how global competition and U.S. policy choices are shaping the future of innovation.Filmed live at JPM, host John Stanford sits down with leaders operating at the ground level, what one panelist calls the “frogs in the mud”, to unpack how capital flows, regulatory signals, and long-term strategy are evolving in real time.Rather than framing innovation as a zero-sum global rivalry, the conversation highlights a more complex reality. The U.S. remains deeply connected to global science, but risks falling behind if domestic policies create friction for innovation.The takeaway is clear. Maintaining U.S. leadership in biotech is not guaranteed. It requires a policy environment that supports discovery, development, and scale while recognizing the growing national security implications of the life sciences.Join the Conversation ⬇️Do you think the U.S. is treating biotech as a national security priority yet?Drop your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTime Stamps0:00 Intro: Is the U.S. losing the biotech arms race?1:10 "Frogs in the Mud": Why D.C. policy misses the mark3:45 The 20-year Chinese strategic plan for biotech6:15 How IRA price controls stifle American innovation9:30 Strategic prioritization: Can the U.S. catch up?12:50 The $350B patent cliff and global market impacts16:20 Navigating the "Valley of Death" for startups20:05 Clinical trial speed: Why China is outperforming the U.S.24:30 SBIR breakthrough: New hope for early-stage funding28:10 The "Playbook for Congress" and the road to 2030DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#Biotech #NationalSecurity #NSCEB #LifeSciences #HealthcareInnovation #BiotechPolicy #Innovation #JPM2026